1. Scrip
  2. >>Business

CAR-T Clinical Hold Adds To 2Seventy’s Headwinds

Abecma Revenues Set To Decline In Q3

 
• By Andrew McConaghie

An early stage CAR-T trial in acute myeloid leukemia has been halted after a patient death, adding to 2Seventy’s difficulties in growing sales of its myeloma treatment Abecma.

Cambridge, MA Massachusetts Avenue and Vassar St on campus on MIT campus
2seventy Bio remains in Cambridge, MA, nearly two years after spinning out from Bluebird Bio. • Source: Shutterstock

2seventy Bio’s Phase I trial of its acute myeloid leukemia CAR-T candidate, SC-DARIC33, in children and young adults has been halted by the US Food and Drug Administration following the death of one of the participants.

The company announced on 14 August that the US Food and Drug Administration had formally placed the study, named PLAT-08, on clinical hold three days earlier, following the report of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip